anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study evaluated the feasibility of the femoral bone after fixation using biphasic calcium phosphate cement-augmentation of the proximal femoral nail antirotation (PFNA) compared with PFNA without cement. This study presented to compare the stiffness, fatigue testing, and compressive strength between stable (AO31-A2.1) and unstable (AO31-A3.3) intertrochanteric fractures treated by cement augmented PFNA of the cadaveric femoral. Biphasic calcium phosphate cement was injected to align and compatible with PFNA and the reconstructive procedure was monitored the cement placement using x-ray imaging during operation. The testing demonstrated that the cement could be injected through a small needle (13 G, 16 cm length, 1.8 mm inner diameter) within a suitable operating time. The feasibility study of the biomechanical testing was divided into three tests: stiffness test, fatigue cyclic load, and compression test. The results showed that the cement-augmented specimens exhibited higher stiffness than the control specimens without cement. The cement-augmented specimens also showed lower strain energy during the fatigue test, resulting in higher compressive strength (4730.7 N) compared to the control specimens (3857.4 N). There is a correlation between BMD and fracture load and the increase in compression load of the cement-augmented femoral compared to the controls as well as an increase in strain energy of fatigue cyclic testing was found. Biphasic calcium phosphate cement-augmented of the PFNA biomechanically enhanced the cut-out resistance in intertrochanteric fracture. This procedure is especially efficient for unstable intertrochanteric fracture suggesting the potential benefits of using biphasic calcium phosphate cement in medical applications.
Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.

All the endoscopic procedures began at 9 AM, and were performed by the same board-certified endoscopist, JMS, who was blinded as to the duration of the fast. The endoscopies were conducted at Gastroclinica, Cuiaba, MT, in the period from April to June, 2013. Sedation was performed by a board-certified anesthesiologist, who was also blinded as to the duration of the fast. The anesthetic regimem included a intravenous bolus of 2 ml of lidocaine hydrochloride (Astra Zeneca, São Paulo, Brazil) followed by 100 to 150mg of propofol before endoscopy. Digital oximetry was monitored throughout the procedure. Patients were positioned in the lateral recumbent position. A flexible electronic videoendoscope (EG2770K; Pentax Corporation, Tokyo, Japan) of 9 mm in outer diameter was used. The main outcome variable was the RGV measured by the endoscopist after aspiration of gastric residue.
<P>PROBLEM TO BE SOLVED: To provide a granulated substance of barley young leaf powder having anticavity effect.  <P>SOLUTION: The granulated substance of barley young leaf powder is obtained by adding water or both of water and ethanol to barley young leaf powder, kneading the mixture, subjecting the kneaded mixture to extrusion molding, and drying the molded mixture. The food is edible as it is, and excellent in palate feeling such as chewiness. The barley young leaf powder contains much dietary fibers and thereby has salivation promoting effect and also excellent anticavity effect. Such anticavity effect is enhanced by adding an anticavity component such as lactobacillus to the barley young leaf powder before granulation.  <P>COPYRIGHT: (C)2003,JPO
Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is \> 24 hours and earlier and earlier is \< 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping. As time progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals moves further and further away from the 24-hour light-dark cycle and gradually, these individuals are unable to sleep at night and as a result experience extreme sleepiness during the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake time moves back into alignment with the social time for sleep and the individuals sleep well at night and have decreased daytime napping. The alignment between their endogenous circadian rhythms and the 24-hour day is temporary as they are continually drifting later and later each day.

The study is comprised of one 24-month treatment phase, as all subjects enrolled in the trial have already been diagnosed with N24HSWD. Frequency of study visits will depend on the subject's prior length of exposure to tasimelteon; accordingly, subjects will be assigned to one of two groups upon enrollment into the study. The short-term exposure group will consist of subjects for which it is possible at screening that they have been exposed to tasimelteon for less than 6 months. The long-term exposure group will consist of subjects who have more than 6 months of exposure to tasimelteon.

After completion of the 24-month treatment phase, subjects have the option to enroll into the optional open-label extension sub-study for an additional 52 weeks. Frequency of visits will be identical regardless of previous exposure (short term/long term).
Low back pain is one of the most common problems in society, experienced by 70-80% of individuals at least once in their lifetime. Physical pain can cause serious functional losses that affect independence in daily life. In patients with low back pain, physical endurance decreases because of pain, spasm, decrease in muscle strength and deteriorated posture, and the functional capacity and quality of life of the patient are negatively affected. While most individuals recover spontaneously, 2-8% of them require medical treatment, and the response to conservative treatment is generally good. Along with medical treatment, different physiotherapy methods (electro-physical agents, massage, traction, exercises, etc.), which are conservative treatment methods, are also frequently used. It is known that classical physiotherapy modalities (heating agents and exercise approaches) have an important place in the treatment of these patients due to their positive effects on pain, strength, flexibility and functionality. Massage is used to systematically manipulate the soft tissues of the body with rhythmic pressure and to provide or maintain health. Basically, massage is a simple way to provide pain relief through physical and mental relaxation. It is thought to relieve pain in various ways, including increasing the pain threshold by secreting endorphins and closing the pain gate at the spinal cord level. Classical massage is considered rehabilitative and is also used to reduce symptoms associated with medical conditions. It has been reported that classical massage reduces many physical and psychological symptoms in different musculoskeletal problems (neck pain, fibromyalgia, etc.). However, there is a need for placebo-controlled studies in the literature examining the effects of classical massage in individuals with chronic low back pain.
Surgical resection is the primary treatment for HCC. However, it is associated with a high rate of recurrence and death. Based on the results of our retrospective study and phase II study, adjuvant radiotherapy is an effective, tolerable, and promising adjuvant regimen in patients with narrow-margin(\<1cm) after hepatectomy. The 3-year and 5-year OS rates of 88.2% and 72.2% were significantly higher than the expected rates based on published reports and exceeded our predetermined threshold. However, there is no standard for the prescription dose. The high risk area of recurrence is mostly close to the blood vessels in the tumor bed, and simultaneously integrated boost (SIB) technique can optimize the target dose while protecting normal tissues. So, the investigators conducted this single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant SIB radiotherapy following narrow-margin(\<1cm) hepatectomy in patients with HCC.
The process comprises detecting pills (2) taken by a patient (3) using a platelet (4) of an electronic circuit (5) for detection and recording the time of extraction of pills belonging to a blister (6), transmitting electrical radio signals from the circuit in real time, capturing and measuring the signals that are transferred in real time or near real time to a remote server to create a data file of observance associated to the patient, and processing the observation data to monitor, improve and/or modify the monitoring of treatment by the patient. The process comprises detecting pills (2) taken by a patient (3) using a platelet (4) of an electronic circuit (5) for detection and recording the time of extraction of pills belonging to a blister (6), transmitting electrical radio signals from the circuit in real time, capturing and measuring the signals that are transferred in real time or near real time to a remote server to create a data file of observance associated to the patient, and processing the observation data to monitor, improve and/or modify the monitoring of treatment by the patient. The platelet is formed of a flexible support on which a part of conductor circuit is printed for forming open interrupters when the pills are manually extracted by the user after adhesion of blister on the platelet. The signals are collected from a telephone connected directly or indirectly to Internet network. The observation data is automatically processed from a control algorithm that determines and transmits it in real time or near real time. The transmitted signals are retransmitted by a text message or telephone call to undertake actions for the patient automatically. Impedance is regularly tested, for detecting positive or negative error, by periodically measuring the voltage and obtaining an average value from 5-10 measurements, comparing the obtained results with the predetermined value, and extracting the pills if the obtained value is greater than a predetermined value. The two pairs of successive average voltages are verified to validate an output pill. An INDEPENDENT CLAIM is included for a system for controlling drug therapy taken in pill form by a patient in real time or near real time.
An integration platform of Internet of Things is provided. An integration platform of Internet of Things comprises a master apparatus, at least one first IOT object and a vendor-side server. The first IOT object comprises a first transmitting and receiving unit and a first device body. The first transmitting and receiving unit is connected to the master apparatus. The first device body is connected to the first transmitting and receiving unit via a way of a wireless communication. The vendor-side server is connected to the master apparatus via a way of a telecommunication. The first cloud simulation object is stored in the vendor-side server. The appearance of the first cloud simulation object is corresponding to an appearance of the first device body. When the first transmitting and receiving unit is connected to the master apparatus for the first time, a first cloud simulation object is transmitted into the controlling map by the vendor-side server. Wherein controlling the first cloud simulation object of the controlling map would operate the first device body corresponding to the first cloud simulation object.
The invention discloses a film coating agent for treating pigeon ectozoa and a preparation method thereof. The ectozoa is feather louse. The film coating agent is composed of the following materials: 8-12 g of ivermectin, 35-45 g of l-menthol, 13-18 g of polyvinyl alcohol-124, 38-42 mg of sodium carboxymethylcellulose, 55-65 ml of glycerin, 500 ml of water, and ethanol added to obtain the constant volume of 1000 ml. The invention also discloses the preparation method of the film coating agent. The film coating agent prepared by the invention has excellent film-forming property, and is capable of slowing releasing anthelmintics, persistent in curative effect, low in stress and safe to use. The formula and the preparation method of the film coating agent are unique and the treatment effect is obvious.
Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
PROBLEM TO BE SOLVED: To obtain a beautifying and whitening dermal preparation for external use, having suppressing actions on melanogenesis and inhibiting actions on tyrosinase activities, capable of manifesting excellent effects on color lightening, beautifying and whitening of pigmentation, dermal stains, ephelides, chloasma, etc., after the sunburn and having high safety. SOLUTION: This beautifying and whitening dermal preparation for external use contains 0.005-20wt.%, preferably 0.01-10wt.% extract of a plant belonging to the genus Eleutherin of the family Iridaceae (e.g. Eleutherin americana Mevr. et Heyne) of extract of a plant belonging to the genus Iris (e.g. Iris pallida) as an active ingredient. The extract, as necessary, is suitably further blended with a beautifying and whitening agent, a humectant, an antioxidant, an oily ingredient, an ultraviolet absorber, a surfactant, a thickening agent, alcohols, a powdery ingredient, a colorant, an aqueous ingredient, water, various dermal nutrients, etc., and prepared into an ointment, a cream, a milky lotion, a lotion, a pack, a bathing agent, etc.  Furthermore, the extract is obtained by immersing or refluxing a leaf, a stem, a fruit, etc., of the plant, the whole herb, etc., thereof together with an extracting solvent (e.g. ethanol) under heating, then filtering the resultant extract and concentrating the prepared filtrate.
OBJECTIVE: The study aimed to assess the level of knowledge of patients with cervical cancer referred to radiation oncology outpatient clinics in Turkey regarding screening methods and human papillomavirus (HPV) vaccination and increase social awareness based on the findings.
METHODS: A descriptive cross-sectional survey was conducted from January to June 2022 involving 300 patients in various regions. Data on demographics, cervical cancer screening and HPV vaccination knowledge, and recommendations to relatives were collected through a questionnaire-based interview. Univariate logistic regression analyzed the impact of independent variables on knowledge levels.
RESULTS: Among the participants, 57% were unaware of cervical cancer screening, and 66% had no knowledge of the HPV vaccine. Higher knowledge levels were associated with higher education, older age at marriage and first birth, and previous gynecological checkups. Lower knowledge levels were observed in patients treated at state institutions, with no formal education, and diagnosed with cervical cancer at age 60 or older. A significant inverse correlation was found between knowledge levels and the stage of cancer at diagnosis, with higher awareness in earlier stages.
CONCLUSION: The study revealed limited awareness among cervical cancer patients in Turkey regarding screening and HPV vaccination. Lower knowledge levels were associated with specific demographic factors, emphasizing the importance of targeted educational campaigns to reduce the burden of cervical cancer and promote early detection. Efforts to enhance vaccination coverage and encourage early screening can significantly improve outcomes. Comprehensive awareness surveys are essential in guiding policymaking and implementing effective early detection and prevention strategies for cervical cancer.
After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
The aim of this protocol is to provide further elucidation of the clinical phenotype of autism, and second to characterize a potential cellular phenotype through the re-programming of fibroblasts into induced pluripotent stem cells (iPS cells). The scope of autistic spectrum disorders (ASD) is defined by its behavioral symptoms, encompassing a group of conditions that includes Asperger disorder, autism and pervasive developmental disorder-not otherwise specified (PDD). The clinical presentation of each of these diagnostic groups differs slightly, but all share three common features: deficits in social reciprocity, delays or deficits in communication (both verbal and non-verbal) and presence of repetitive behaviors and fixated interests. These symptoms are most pronounced in the autism group, so they will serve as the subjects for this pilot investigation. Individual differences in behavioral symptoms, genetic abnormalities, medical comorbidities and other risk factors will be assessed. These approaches will be coupled with computational approaches to identify neural networks by analysis of gene association study data, and analysis of gene databases to relate the diagnostic criteria of autism by unbiased analysis of the ontology of genes relevant to CNS function.
Three randomized, multi-center, double-blind, placebo-controlled trials (BLESS I [NCT02677298], BLESS II [NCT02677805] and BLESS III [NCT03985982]) of identical design were conducted to evaluate LETYBO for use in the temporary improvement of the appearance of moderate to severe glabellar facial lines. These trials enrolled 1,276 subjects, randomized 3 to 1 to a single treatment with LETYBO (n=957) or placebo (n=319). Of the 1,276 enrolled subjects, 1,271 were included in the full analysis set (FAS) evaluable for efficacy with LETYBO (n=954) and placebo (n=317).

The trials enrolled healthy adults (ranging in age from 19 to 75) with glabellar lines of at least moderate severity at maximum frown and excluded subjects who had ptosis, deep dermal scarring or an inability to substantially lessen glabellar lines even by physically spreading the glabellar lines apart. The mean age was 50 years with 152 subjects (12%) ≥65 years of age. Most of the subjects were women (91%) and White (91%). Injection volume was 0.1 mL/injection site, for a dose/injection site in the active treatment groups of 4 Units. Subjects were injected intramuscularly at 5 sites, 1 in the procerus muscle and 2 in each corrugator supercilii muscle, for a total dose in the active treatment groups of 20 Units.

The primary efficacy endpoint was measured at Week 4 and was defined as the proportion of subjects achieving a score of 0 or 1 and an improvement of at least 2 points from baseline at maximum frown, as assessed independently by both the investigator and the subject using the Glabellar Line Scale (GLS). The GLS is a 4-point grading scale (0=none, 1=mild, 2=moderate, 3=severe). The results of these 3 efficacy trials are presented in Table 3.
Dialysis patients have limited physical functioning as measured by self-reported functioning, peak oxygen consumption, physical performance tests, and tests of muscle strength. A recent study highlighted the severity of debility, reporting that more than one third of hemodialysis patients were unable to perform the normal activities of daily living without assistance. In addition, physical functioning has been shown to be a major determinant of patients' assessment of their global quality of life. Taken together, available evidence suggests that impaired physical functioning is widespread among dialysis patients and profoundly affects their lives. Therefore, interventions to improve functioning in this population have the potential to significantly improve quality of life.

Muscle wasting and weakness are particularly attractive targets for intervention because they are related to loss of function and can be objectively measured and targeted for improvement. Small studies support the possible benefits of two strategies to increase muscle size and strength among patients on dialysis. Anabolic steroids were frequently used to ameliorate the anemia associated with end-stage renal disease prior to the introduction of recombinant erythropoietin, and these agents were noted to cause an increase in serum creatinine along with increases in hemoglobin and hematocrit. More recently, nandrolone decanoate has been shown to increase lean body mass and improve physical performance, and resistance exercise training has been shown to increase strength and improve physical performance. Neither of these preliminary results has been confirmed, nor have the relative benefits of these strategies or their potential additive or synergistic effects been examined. Therefore, we designed a study to compare changes in lean body mass, muscle size and strength, physical performance, and self-reported functioning over a12 week period among hemodialysis patients randomly assigned to one of four groups: 1) nandrolone decanoate, a synthetic testosterone derivative, by weekly intramuscular injection (ND); 2) weekly placebo injections (PL); 3) lower extremity resistance exercise training during dialysis sessions three times per week plus weekly placebo injections (EX); and 4) resistance exercise plus nandrolone injections weekly (EX+ND).
Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
<P>PROBLEM TO BE SOLVED: To provide a DNA encoding a non-naturally occurring HCV that is capable of peplication.  <P>SOLUTION: The HCV variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein encoding regions. The variants include expression vectors comprising the above polynucleotides and HCV variants, cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV, and vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier are also provided. Additionally, methods for inducing immunoprotection to HCV in a primate, and methods for testing a compound for inhibiting HCV replication are disclosed.  <P>COPYRIGHT: (C)2007,JPO&INPIT